CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice

Bone marrow failure and hematopoietic damage is one of the major consequences of irradiation-induced lethality. There is an immediate need to develop medical countermeasures (MCMs) to combat irradiation-induced lethality. We tested the efficacy of CDX-301, developed by Celldex Therapeutics Inc., in...

Descripción completa

Detalles Bibliográficos
Autores principales: Satyamitra, Merriline, Cary, Lynnette, Dunn, Dylan, Holmes-Hampton, Gregory P., Thomas, Lawrence J., Ghosh, Sanchita P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000413/
https://www.ncbi.nlm.nih.gov/pubmed/32019942
http://dx.doi.org/10.1038/s41598-020-58186-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000413/
https://www.ncbi.nlm.nih.gov/pubmed/32019942
http://dx.doi.org/10.1038/s41598-020-58186-1

Ejemplares similares